Well, there you go, I guess. So high semaglutide pricing won't end up "bankrupting" the US medical system. It'll push an ever larger number of patients -- and

Well, there you go, I guess. So high semaglutide pricing won't end up "bankrupting" the US medical system. It'll push an ever larger number of patients -- and more than a few well-meaning doctors, who already recommend things like BPC-157 -- into the gray market. That this would further delegitimize the medical establishment and FDA would be a well-deserved outcome.